Dong-A ST Co., Ltd. (170900.KS) Stock
Dong-A ST Co., Ltd.

Company profile
Dong-A ST reported revenue of 808.78 billion KRW for fiscal year 2025, up 15.9% from fiscal year 2024. In Q1 2026 (the quarter ended March 31, 2026) revenue was 203.58 billion KRW, up 11.8% from a year before. South Korea was its largest region in fiscal year 2025, with 76% of revenue. In Q1 2026 it reported net income of 8.66 billion KRW, against a net loss of 8.17 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 663.98 billion KRW in fiscal year 2023 to 808.78 billion KRW in fiscal year 2025, 10.4% a year on average. Dong-A ST reports about 1,649 full-time employees.
What stands out
- It reported a net loss in each of its last 2 fiscal years, after a profit of 11.12 billion KRW in fiscal year 2023; the loss widened from 1.22 billion KRW in fiscal year 2024 to 28.59 billion KRW in fiscal year 2025.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Dong-A ST Co., Ltd.
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature, small for gestational age, turner syndrome; Leucostim Inj. for neutropenia in patients receiving myelosuppressive chemotherapy; Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab. for use in functional dyspepsia treatment; Stillen tab/ Stillen 2X tab. to treat gastritis; Suganon tab./Sugamet XR tab. and Sugadapa tab./Sugatree XR tab for type 2 diabetes mellitus; DA-3880 PFS to treat renal anemia and darbepoetin-alfa; and Zydena tab. for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.
Largest shareholders
- Dong-A Socio Holdings Co., Ltd.26.17%
- Gsk PLC7.95%
- Otsuka Holdings Co., Ltd.5.97%
- National Pension Service of Korea4.78%
- Sooseok Foundation0.49%
Share of the company, as of September 25, 2026
Leadership
- Jae-Hun Jung — CEO, President & Director, 54
- Jae-Hong Park — President & Director, 56
- GyuHong Jo — Managing Director
- SunJong So — Managing Director
- Yu-Seok Shin — Managing Director
In the news
- XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
- Dong-A ST Demonstrates Therapeutic Equivalence Between DMB-3115 and Stelara in Global Phase III
- Dong-A ST Signs License-out Deal with Polifarma of Türkiye for NESP® Biosimilar DA-3880
- NeuroBo Shares Surge On Licensing, Equity Investment Pact With Korean Pharma Firm
How much revenue does Dong-A ST make?
Dong-A ST reported 808.78 billion KRW in revenue for fiscal year 2025, up 15.9% from 697.87 billion KRW in fiscal year 2024. In Q1 2026 revenue was 203.58 billion KRW.
Where does Dong-A ST make most of its revenue?
South Korea: 76% of revenue by region in fiscal year 2025, followed by Southeast Asia (11%).
What companies are similar to Dong-A ST?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ildong Pharmaceutical Co., Ltd. (249420.KS), Bukwang Pharmaceutical Co., Ltd. (003000.KS), AprilBio Co.,Ltd. (397030.KQ), HLB Pharmaceutical Co., Ltd. (047920.KQ).
Has Dong-A ST made a profit in recent years?
Net income by fiscal year: FY2021, 12.82 billion KRW; FY2022, 13.55 billion KRW; FY2023, 11.12 billion KRW; FY2024, a loss of 1.22 billion KRW; FY2025, a loss of 28.59 billion KRW. It reported a net loss in 2 of these 5 years.
How has Dong-A ST's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 593.23 billion KRW; FY2022, 635.39 billion KRW; FY2023, 663.98 billion KRW; FY2024, 697.87 billion KRW; FY2025, 808.78 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Dong-A ST Co., Ltd. (170900.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/170900.KS